Tag: drug_approval

FDA Approves Columbia-Backed Pancreatic Cancer Drug Daraxonrasib

28 Aug 2026 3:00 p.m. · Source: Columbia University

Daraxonrasib, a new targeted therapy supported by Columbia research, has received FDA approval for pancreatic cancer, nearly doubling overall survival in metastatic patients and marking a significant breakthrough.

Health Science & Technology Business Education Medical Science Environment Artificial Intelligence Economy Social Issues Asia Daraxonrasib Pancreatic Cancer Columbia University FDA Oncology Clinical Trials Drug Approval newsletter